{"filing":{"accession_number":"0001213900-26-087506","cik":"0001359931","ticker":"TARA","company_name":"Protara Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-11","report_date":"2026-08-11","primary_document":"ea0299236-8k_protara.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390026087506/ea0299236-8k_protara.htm"},"events":[{"id":26906,"run_id":24473,"accession_number":"0001213900-26-087506","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"The filing discloses Protara Therapeutics' financial results for the second quarter ended June 30, 2026, including a net loss of $21.7 million ($0.36 per share), R\u0026D expenses of $17.0 million, G\u0026A expenses of $6.4 million, and cash position of $161.9 million. The press release attached as Exhibit 99.1 is a standard quarterly earnings announcement with financial statements and business updates, filed under Item 2.02 (Results of Operations and Financial Condition).","company_name":"Protara Therapeutics, Inc.","ticker":"TARA","filing_date":"2026-08-11","form":"8-K","submitted_at":null,"items":[{"id":28201,"accession_number":"0001213900-26-087506","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Protara Therapeutics' financial results for the second quarter ended June 30, 2026, including a net loss of $21.7 million ($0.36 per share), R\u0026D expenses of $17.0 million, G\u0026A expenses of $6.4 million, and cash position of $161.9 million. The press release attached as Exhibit 99.1 is a standard quarterly earnings announcement with financial statements and business updates, filed under Item 2.02 (Results of Operations and Financial Condition).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T12:06:53.569925+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28201,"accession_number":"0001213900-26-087506","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Protara Therapeutics' financial results for the second quarter ended June 30, 2026, including a net loss of $21.7 million ($0.36 per share), R\u0026D expenses of $17.0 million, G\u0026A expenses of $6.4 million, and cash position of $161.9 million. The press release attached as Exhibit 99.1 is a standard quarterly earnings announcement with financial statements and business updates, filed under Item 2.02 (Results of Operations and Financial Condition).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T12:06:53.569925+00:00","company_name":"Protara Therapeutics, Inc.","ticker":"TARA","filing_date":"2026-08-11"}]}